osteolabs GmbH

Calcium Isotope Marker Technology: A novel, highly sensitive diagnostic platform for early detection of bone-related disorders

• Our mission: Turn Coral Research into Clinical Diagnostics for > 1 Billion patients lacking efficient tools for Early Diagnosis of bone-related disorders with a high unmet need.
   
• Calcium Isotope Marker (CIM) technology provides highly sensitive insights into Bone Calcium Balance (BCaB)/Calcium Homeostasis through measurement of 44Ca/42Ca Isotope Fractination representing a noel & universal Biomarker Class as single test principle for highly burdensome diseases.
   
• Significant clinical validation with over 3,000 samples for fracture risk prevention, detection and monitoring but also early detection of Bone Metastases through use of newly developed ProstaTest.
   
• Newly developed RenaTest: Correct classification of CKD patient status and early detection of Renal Osteodystrophy.
   
• With a strong team of 20+ people in place we have started to execute our Business Plan with focus on Scale-up and rapid Market Penetration of all test formats in order to address multimillion/billion market opportunities.
   
• CIM technology has clear 100M+ revenue potential over next 10 years with appropriate financial backing and hence represents an attractive investment opportunity before take-off.